The DOI matches its Crossref record; 126 of the 127 references it cites were found in a registry or an index; 15 of the 117 sources its claims cite were checked for support.
Obesity pharmacotherapy in older adults: a narrative review of evidence
Open accessAbstract
The prevalence of obesity in older adults (people aged >60 years) is increasing in line with the demographic shift in global populations. Despite knowledge of obesity-related complications in younger adults (increased risk of type 2 diabetes, liver and cardiovascular disease and malignancy), these considerations may be outweighed, in older adults, by concerns regarding weight-loss induced reduction in skeletal muscle and bone mass, and the awareness of the ‘obesity paradox’. Obesity in the elderly contributes to various obesity-related complications from cardiometabolic disease and cancer, to functional decline, worsening cognition, and quality of life, that will have already suffered an age-related decline. Lifestyle interventions remain the cornerstone of obesity management in older adults, with emphasis on resistance training for muscle strength and bone mineral density preservation. However, in older adults with obesity refractory to lifestyle strategies, pharmacotherapy, using anti-obesity medicines (AOMs), can be a useful adjunct. Recent evidence suggests that intentional weight loss in older adults with overweight and obesity is effective and safe, hence a diminishing reluctance to use AOMs in this more vulnerable population. Despite nine AOMs being currently approved for the treatment of obesity, limited clinical trial evidence in older adults predominantly focuses on incretin therapy with glucagon-like peptide-1 receptor agonists (liraglutide, semaglutide, and tirzepatide). AOMs enhance weight loss and reduce cardiometabolic events, while maintaining muscle mass. Future randomised controlled trials should specifically evaluate the effectiveness of novel AOMs for long-term weight management in older adults with obesity, carefully considering the impact on body composition and functional ability, as well as health economics.
Overview
CoChat Summary
TL;DR
This narrative review concludes that obesity pharmacotherapy can be a useful adjunct to lifestyle intervention in older adults (>60 years), with incretin-based anti-obesity medicines producing clinically meaningful weight loss and cardiometabolic benefit while concerns about muscle and bone loss remain. It highlights that trial evidence specifically in older adults is scarce, often limited by upper age limits and poor reporting of older participants, and calls for future RCTs focused on body composition, function, and health economics.
Key findings
- Obesity prevalence is rising in older adults, with ~20% of this age group now living with a BMI ≥30 kg/m²; intentional weight loss in older adults with overweight/obesity appears effective and safe, though concerns include weight-loss-induced reduction in skeletal muscle and bone mass and the “obesity paradox.”
- Nine anti-obesity medicines (AOMs) are FDA-approved and seven are EMA-approved, but older-adult trial evidence is scarce and predominantly focuses on incretin therapy: liraglutide, semaglutide, and tirzepatide. Many trials included older adults but had upper age limits, resulting in little data for people in their 80s.
- Landmark trial weight losses include liraglutide 3 mg 8% vs 2.6% with placebo over 56 weeks (SCALE-Obesity and Prediabetes); semaglutide 2.4 mg 14.8% vs 2.4% over 68 weeks (STEP-1), with 86.4% achieving ≥5% weight loss; tirzepatide 15 mg 20.9% vs 3.1% at 72 weeks (SURMOUNT-1); and retatrutide highest dose 24.2% at 48 weeks.
- AOMs may improve cardiometabolic outcomes while preserving muscle mass; SELECT found MACE reduced by 20% with semaglutide, and pooled SURMOUNT-1/SURPASS-2 data showed reduced MACEs and cardiovascular death by 48% and 49%, respectively.
Methods
- Narrative review of evidence for obesity pharmacotherapy in older adults (people aged >60 years), synthesizing clinical trials, meta-analyses, observational studies, guidelines, and drug approval information.
- Data from clinical trials for approved and future AOMs with evidence in older adults are presented in tables, including RCT sample size, BMI, age, follow-up, mean weight loss, proportion achieving ≥5% weight loss, and side effects, plus dosing and management algorithms.
- Main analysis is a narrative/descriptive synthesis; no systematic search strategy, formal risk-of-bias assessment, or pooled effect estimate is reported.
Limitations
- The paper states that scarce evidence exists for AOMs in older adults; many trials may have included older adults but had upper age limits, and the Summary of Product Characteristics states that therapeutic experience in patients ≥75 years is limited.
- The paper states that obesity paradox evidence is heavily confounded by whether weight loss is intentional and by use of BMI, which poorly reflects body composition in older adults; future RCTs should specifically evaluate long-term weight management, body composition, functional ability, and health economics.
- Evident from the text: this is a narrative review without a systematic search or formal quality appraisal, and many cited trials were not designed exclusively for older adults or relied on subgroup/pooled analyses, limiting certainty for this population.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Venn diagram exploring the four body composite phenotypes in older adults (including healthy weight). The triad of sarcopenia, as defined by The European Working Group on Sarcopenia in Older People (EWGSOP), is illustrated [35]. Co-morbid complications related to obesity include, but are not limited to, cardiovascular disease (CVD), metabolic dysfunction associated steatotic liver disease (MASLD), type 2 diabetes (T2D), hormone-dependant cancers, and musculoskeletal (MSK) issues such as osteoarthritis.](https://figures.cochat.ai/paper-figures/c834b4833c594cd9b9eccdc22a2b9343/obesity-pharmacotherapy-in-older-adults-a-narrative-review-of-evidence-figure-1.jpg)



Verification
Claims the paper makes
13 Valid · 2 Not valid · 73 Not checked · 9 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“It is believed this potential protective effect of living with obesity in older adults is restricted to those living only with overweight/lesser degrees of obesity [7]”
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Introduction
What the sources say
- Partly supportedcites [7] Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309:71–82. sourceExperimental — accuracy not yet measured
Table 2 reports lower all-cause mortality for adults aged 65 or older with overweight (HR 0.90), but the estimate for grade 1 obesity (HR 0.88, 95% CI 0.69–1.12) does not establish a protective effect. The estimate for grades 2 and 3 obesity is higher (HR 1.28), though also uncertain (95% CI 0.93–1.76). The pattern is consistent with the claim’s proposed restriction, but the age-specific results do not establish it. (LLM, conf=0.86)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A meta-analysis of observational studies in older adults raised concerns regarding weight loss and mortality outcomes. Weight loss was associated with a 59% increase in mortality risk.”
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Impact of weight loss on older adults > Mortality
What the sources say
- Supportedcites [63] Alharbi TA, Paudel S, Gasevic D, Ryan J, Freak-Poli R, Owen AJ. The association of weight change and all-cause mortality in older adults: a systematic review and meta-analysis. Age Ageing. 2021;50:697–704. source
The Abstract (p.1) and the Results section 'Weight loss and the risk of all-cause mortality' both report that, across 30 prospective observational studies (1,219,279 participants, 69,255 all-cause deaths), adults aged ≥65 with weight loss had a 59% increased risk of all-cause mortality (HR 1.59; 95%CI 1.45-1.74). This matches the claim's design (meta-analysis of observational studies), population (older adults) and magnitude (59%). The only unstated qualifier is that the included studies were community-dwelling older adults. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recent prospectively designed studies have found higher WC increases CVD risk in older adults [27, 28]”
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Age-related changes in body composition and their sequelae > Cardiometabolic disease
What the sources say
- Partly supportedcites [27] Dey DK, Lissner L. Obesity in 70-year-old subjects as a risk factor for 15-year coronary heart disease incidence. Obes Res. 2003;11:817–27. sourceExperimental — accuracy not yet measured
The cited study is prospective (H70, Gothenburg; WC/BMI measured at age 70, 15-year follow-up to age 85) and does report higher WC predicting first-ever CHD, but only in men: the Results ('WC and CHD') give RR 1.36 (95% CI 1.00-1.85) in the highest WC quartile in males with a significant linear trend (p=0.033), whereas in females RR was 1.08 (0.76-1.47) and the highest RR (1.30, 0.93-1.79) occurred in the second quartile. The Discussion states plainly that 'neither a high WC nor a high BMI was a significant risk factor for CHD in elderly females' and concludes 'both BMI and WC are risk factors for CHD in elderly males but not in females.' So the source supports the claim for older men but not for older adults generally, and its outcome is coronary heart disease rather than cardiovascular disease broadly. (LLM, conf=0.80)
- Not checked yetcites [28] Visscher TL, Seidell JC, Molarius A, van der Kuip D, Hofman A, Witteman JC. A comparison of body mass index, waist-hip ratio and waist circumference as predictors of all-cause mortality among the elderly: the Rotterdam study. Int J Obes Relat Metab Disord. 2001;25:1730–5. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Weight loss of 5–10% total body weight can improve physical function and such cardiometabolic risk factors as blood pressure and lipid profile, whilst weight loss exceeding 10% can additionally improve cancer risk, fertility, and health-care costs, while further improving cardiometabolic outcomes [43, 44].”
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Impact of weight loss on older adults
What the sources say
- Not checked yetcites [43] Tahrani AA, Morton J. Benefits of weight loss of 10% or more in patients with overweight or obesity: a review. Obesity. 2022;30:802–40. source
- Partly supportedcites [44] Ryan DH, Yockey SR. Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep. 2017;6:187–94. sourceExperimental — accuracy not yet measured
The Abstract reports that 5–10% weight loss is associated with improvements in blood pressure, HDL cholesterol, and mobility; the cardiovascular-risk-factor section also reports improvements in triglycerides. The claim’s restriction to younger adults is not supported: the paper does not establish these combined benefits specifically for that age group. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Generally, each kilogram of body weight lost constitutes ~75% fat mass and ~25% muscle mass [46], although the relationship is non-linear and governed by the magnitude of weight loss [47].”
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Impact of weight loss on older adults > Morbidity
What the sources say
- Partly supportedcites [46] Santanasto AJ, Glynn NW, Newman MA, Taylor CA, Brooks MM, Goodpaster BH, et al. Impact of weight loss on physical function with changes in strength, muscle mass, and muscle fat infiltration in overweight to moderately obese older adults: a randomized clinical trial. J Obes. 2011;2011:516576. sourceExperimental — accuracy not yet measured
Results §3.3 (page unavailable) reports that the weight-loss group lost an average of 4.9 kg of body weight and 4.4 kg of body fat; §3.4 also reports a loss of thigh muscle area. The paper therefore supports loss of both fat and muscle, but it does not establish the claimed general 75% fat/25% muscle split per kilogram lost. (LLM, conf=0.88)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
49 more claims · 2 with their cited sources checked
Create a free account to see all 97 claims and to verify the 102 references still open.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AEs are more frequent in older adults compared to young adults, and they are particularly noted to occur during dose escalation [12, 43, 57, 75].”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the most common adverse events (AEs) of treatment are mild to moderate gastrointestinal including nausea, vomiting, diarrhea, constipation, dyspepsia, and decreased appetite.”
From GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity (2026) · doi:10.1007/s13668-026-00777-x · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Evidence for efficacy and safety of approved anti-obesity medicines in older adults
“| Tirzepatide | SURPASS-2 (1879) [102] | 34.2 | 56.6, no upper limit | 40 | 13 (80) | Nausea, diarrhoea, and constipation |”
§ Obesity pharmacotherapy in older adults: a narrative review of evidence > Evidence for efficacy and safety of approved anti-obesity medicines in older adults > Mixed centrally and peripherally acting anti-obesity medicines with evidence for use in older adults
“SURPASS-2 demonstrated greater efficacy in the treatment of T2D compared to semaglutide in an older population (mean age 56.6 years, with no upper limit) [103].”
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) · JAMA · doi:10.1001/jama.2012.113905 · Cited by 3,998
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“In total, 85%, 89%, and 91% of participants lost 5% bodyweight with 5, 10, and 15 mg of tirzepatide, respectively (vs. 35% with placebo) [102].”
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afz046 · Cited by 3,803
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citationAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Cited by
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai, H., Li, Y., Lee, Y. A., Lu, Y., George, T. J., Donahoo, W. T., Lee, K. P., Nakshatri, H., Allen, J. M., Guo, Y. M., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2681 · Cited by 124
Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
Walker, C. S., Aitken, J. F., Amarsingh, G. V., Zhang, S., & Cooper, G. J. S. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01125-9 · Cited by 40
Aldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 24
Salladay-Perez, I. A., Avila, I., Estrada, L., Alexandru, A. C., Ponce, C., Dhingra, A., Torres, G., Deng, C. Y., Hegde, R., Gensheimer, J., et al. (2026) · Nature Aging · doi:10.1038/s43587-026-01101-6 · Cited by 30
Barazzoni, R., Sievenpiper, J. L., Genton, L., Kendall, C. W. C., Ballesteros-Pomar, M. D., Giosuè, A., Boirie, Y., Chiavaroli, L., Cederholm, T., Aas, A., et al. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.10.007 · Cited by 19
Metadata
- Authors
- Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J.
- Affiliations
- University of Liverpool (GB)
- Corresponding author
- Henney, Alex E.
- Venue
- International Journal of Obesity
- Published
- 2024-05-06
- Volume
- 49
- Issue
- 3
- Pages
- 369-380
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- PMC
- PMC11971046
- OpenAlex
- W4396673812
- Cited by
- 51
- References
- 127
- Citations by year
- 2026: 22 · 2025: 27 · 2024: 2
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- International Journal of Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity pharmacotherapy, older adults, weight loss, obesity paradox, sarcopenia, bone mineral density, incretin-based therapy, GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide, cardiometabolic disease, functional decline, body composition, resistance training
- MeSH terms
- Aged, Humans, Middle Aged, Obesity, Weight Loss, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Obesity pharmacotherapy in older adults: a narrative review of evidence. https://app.cochat.ai/papers/10.1038/s41366-024-01529-z
- The paper
- Henney, A. E., Wilding, J. P. H., Alam, U., & Cuthbertson, D. J. (2025). Obesity pharmacotherapy in older adults: a narrative review of evidence. International Journal of Obesity. https://doi.org/10.1038/s41366-024-01529-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.